The UK company Beckley Psytech is the latest biotech to raise investor funding to support the evaluation of psychedelic compounds, and in particular the serotonin 5HT2-alpha agonist, psilocybin, as potential therapeutics, a sector that has seen companies marshalling resources to develop their candidates, often with weighty financial backing.
For example, the Berlin, Germany-based company atai Life Sciences BV raised $258.8m in gross proceeds from an IPO...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
